13F Holdings
中文EN

QNTM Quantum Biopharma Ltd. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1771885 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)-230.2%
Asset turnover—

Leverage & solvency

Liabilities / assets54.3%
Debt / equity0.00x
Current ratio1.07x
Interest coverage-96.81x

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue—————
R&D expense$2.76M$6.08M$3.86M$6.91M$6.33M
SG&A expense$9.05M$9.41M$9.03M$14.45M$15.93M
Operating income-$15.30M-$16.14M-$23.79M-$27.43M-$33.74M
Interest expense$158,063$33,017$299$63,411$69,404
Net income———$0$0
EBITDA-$14.76M-$15.65M-$21.28M-$22.89M-$29.70M
EPS (diluted)—————
Weighted avg. shares (diluted)—1.14M609,056595,88334.95M
Banking
Net interest income$236,084$572,891$786,363$367,735$1,292
Balance sheet
Cash & equivalents$1.91M$6.00M$2.76M$16.98M$35.26M
Short-term investments$459,080$1.20M$756,100$0$158,036
Receivables——$209,550$374,377$500,964
Inventory$52,133$117,242$0——
Current assets$6.48M$12.05M$11.09M$17.85M$45.93M
PP&E, netmay include right-of-use assets (IFRS)$67,029$76,894$87,583$105,729$0
Intangibles$4.51M$4.93M$5.36M$12.04M$16.20M
Total assets$11.16M$17.12M$17.47M$38.41M$62.96M
Current liabilities$6.06M$6.68M$4.57M$7.83M$8.70M
Total liabilities$6.06M$6.68M$4.57M$7.87M$8.83M
Shareholders' equity$6.92M$11.48M$13.24M$30.54M$54.13M
Cash flow statement
Operating cash flow-$8.24M-$6.88M-$10.83M-$28.33M-$20.75M
Capital expenditure—$0$0$113,958$0
Free cash flow—-$6.88M-$10.83M-$28.45M-$20.75M
Investing cash flow-$1.95M-$1.50M-$269,579$12.12M$268,964
Financing cash flow$6.10M$11.62M-$3.13M-$2.07M$38.21M
Depreciation & amortization$545,780$490,571$2.51M$4.54M$4.05M
Stock-based compensation$2.95M$152,214$3.84M$1.53M$7.44M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.